Ascendis Pharma/$ASND
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Ticker
$ASND
Sector
Primary listing
Employees
1,017
Headquarters
Hellerup, Denmark
Website
Ascendis Pharma Metrics
BasicAdvanced
$13B
-
-$5.31
0.41
-
Price and volume
Market cap
$13B
Beta
0.41
52-week high
$216.45
52-week low
$118.03
Average daily volume
447K
Financial strength
Current ratio
1.019
Quick ratio
0.658
Long term debt to equity
-176.032
Total debt to equity
-422.523
Interest coverage (TTM)
-2.99%
Profitability
EBITDA (TTM)
-289.189
Gross margin (TTM)
84.88%
Net profit margin (TTM)
-55.25%
Operating margin (TTM)
-51.66%
Effective tax rate (TTM)
-2.66%
Revenue per employee (TTM)
$558,360
Management effectiveness
Return on assets (TTM)
-17.17%
Return on equity (TTM)
106.60%
Valuation
Price to revenue (TTM)
21.424
Price to book
-66.41
Price to tangible book (TTM)
-65.09
Price to free cash flow (TTM)
-61.524
Free cash flow yield (TTM)
-1.63%
Free cash flow per share (TTM)
-3.344
Growth
Revenue change (TTM)
54.50%
Earnings per share change (TTM)
-47.07%
3-year revenue growth (CAGR)
195.60%
10-year revenue growth (CAGR)
47.45%
3-year earnings per share growth (CAGR)
-13.38%
10-year earnings per share growth (CAGR)
14.37%
What the Analysts think about Ascendis Pharma
Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.
Bulls say / Bears say
Ascendis Pharma’s Q2 2025 revenue of EUR 158.05 million exceeded analyst expectations of EUR 142.38 million, driven by strong sales of YORVIPATH and SKYTROFA, resulting in a 2.9% stock gain post-announcement (Reuters)
YORVIPATH (TransCon PTH) generated EUR 103.0 million in Q2 2025, with approximately 3,100 unique patient enrollments and over 1,500 U.S. prescribers, demonstrating robust commercial adoption (Reuters)
The FDA has accepted the NDA for TransCon CNP (navepegritide) for priority review, granting a PDUFA goal date of November 30, 2025, which, if approved, could add a third high-value medicine to Ascendis’s portfolio (Ascendis Pharma)
Ascendis Pharma remains unprofitable, reporting a Q2 2025 loss of EUR 0.82 per share despite revenue growth, highlighting ongoing challenges in reaching profitability (Reuters)
Selling, general, and administrative expenses surged to EUR 107.6 million in Q2 2025 from EUR 74.3 million a year earlier, underscoring increasing burn rates from continued commercial expansion (Reuters)
TransCon CNP’s U.S. approval remains uncertain as its NDA is under FDA priority review with a PDUFA date set for November 30, 2025, introducing significant execution risk for the company’s growth disorders franchise (Ascendis Pharma)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Ascendis Pharma Financial Performance
Revenues and expenses
Ascendis Pharma Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ascendis Pharma stock?
Ascendis Pharma (ASND) has a market cap of $13B as of October 30, 2025.
What is the P/E ratio for Ascendis Pharma stock?
The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 0 as of October 30, 2025.
Does Ascendis Pharma stock pay dividends?
No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of October 30, 2025.
When is the next Ascendis Pharma dividend payment date?
Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ascendis Pharma?
Ascendis Pharma (ASND) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.